Drugs Made In America Acquisition Corp. Ordinary Shares
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMAA research report →
Price Chart
About the company
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses.
- CEO
- Roger Bendelac
- IPO
- 2025
- Employees
- 2
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DMAA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $264.62M
- P/E
- 61.83
- PEG
- -0.62
- P/S
- 0.00
- P/B
- -17.59
- EV/EBITDA
- -107.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 3.46%
- ROIC
- -1.70%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-2,816,013
- Net Income
- $5.94M+1240317.7%
- EPS
- $0.19+439.3%
- OCF Growth
- -182675.3%
- FCF Growth
- -182675.3%
- 52W High
- $10.91
- 52W Low
- $10.32
- 50D MA
- $10.87
- 200D MA
- $10.67
- Beta
- 0.00
- RSI (14)
- 76
- Avg Volume
- 22.01K
No earnings-call transcripts are available for DMAA yet.
- Free Float
- 81.5%
- Shares Outstanding
- 24.28M
- Float Shares
- 19.79M
of shares held by institutions
23 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mizuho Securities Usa LLC | 4.40M | ▲ 2.33M |
| Karpus Management, Inc. | 2.49M | ▼ 14.13K |
| Polar Asset Management Partners Inc. | 1.15M | 0 |
| Glazer Capital, LLC | 855.98K | ▼ 143.92K |
| Wolverine Asset Management LLC | 851.99K | ▲ 19.90K |
| First Trust Capital Management L.P. | 786.46K | 0 |
| Highbridge Capital Management LLC | 684.54K | ▼ 124.52K |
| Heights Capital Management, Inc | 631.34K | ▼ 16.74K |
| Westchester Capital Management, LLC | 581.79K | 0 |
| Crossingbridge Advisors, LLC | 374.87K | ▲ 374.87K |
| Aristeia Capital, L.L.C. | 329.64K | ▼ 20.36K |
| Clear Street Group Inc. | 306.01K | ▼ 76.43K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 18, 25 | Drugs Made In America Acquisition LLC | buy | 30,000 |
| Feb 18, 25 | Drugs Made In America Acquisition LLC | buy | 30,000 |
| Feb 18, 25 | Stockwell Lynn | buy | 30,000 |
| Feb 18, 25 | Stockwell Lynn | buy | 30,000 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | buy | 400,000 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | other | 400,000 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | sell | 5,698,363 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | buy | 400,000 |
| Jan 29, 25 | Stockwell Lynn | other | 400,000 |
| Jan 29, 25 | Stockwell Lynn | sell | 5,698,363 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DMAA coverage
Recent articles, reports, and earnings notes.
No research on DMAA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DMAA report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.